SALSA MLPA Probemix P043 APC detects copy number variations in the APC and MUTYH genes, and in the upstream region of the GREM1 gene.
Contents: 45 MLPA probes, including 29 probes for APC, 4 probes for MUTYH, 2 probes for the region upstream of GREM1 and 2 probes for MUTYH point mutations c.536A>G and c.1187G>A.
Tissue: genomic DNA isolated from human peripheral whole blood.
Application: familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), and hereditary mixed polyposis syndrome (HMPS).
IVDR certified and registered for in vitro diagnostic (IVD) use in selected territories.
This product has recently been CE-marked for in vitro diagnostic (IVD) use under the In Vitro Diagnostic Regulation (IVDR; EU 2017/746), which replaces the former CE-marking under the IVD Directive (IVDD; Directive 98/79/EC). This update was accompanied by a change in the intended purpose and a change in format of the product description. Some information can now be found in a different location (more information).
Compare Lynch syndrome and polyposis syndrome products from MRC Holland.
The SALSA MLPA Probemix P043 APC is an in vitro diagnostic (IVD) or research use only (RUO) semi-quantitative manual assay for the detection of deletions and duplications in the APC gene in order to confirm a potential cause for and clinical diagnosis of familial adenomatous polyposis (FAP). Additionally, P043 APC is intended for the detection of deletions in the MUTYH gene in order to confirm a potential cause for and clinical diagnosis of MUTYH-associated polyposis (MAP). This probemix can also detect the presence of the two most common point mutations in the MUTYH gene among people from European descent: c.536A>G (p.Tyr179Cys) and c.1187G>A (p.Gly396Asp). Moreover, P043 APC is intended for the detection of duplications in the upstream region of the GREM1 gene in order to confirm a potential cause for and clinical diagnosis of hereditary mixed polyposis syndrome (HMPS1). P043 APC is also intended for molecular genetic testing of at-risk family member. This probemix is to be used with genomic DNA isolated from human peripheral whole blood specimens.
For the full intended purpose, see the product description.
Germline defects in the APC gene are the most frequent cause of a hereditary predisposition to polyposis colon cancer, which can present as familial adenomatous polyposis (FAP), attenuated FAP (AFAP), or gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). In addition, acquired mutations in the APC gene are an initiating event for sporadic colorectal tumour development. Most FAP patients develop adenomatous colonic polyps in the first two decades of life and in untreated individuals this progresses into colonic cancer at an average age of 39 years. APC-related colorectal cancer (CRC) is a dominant trait. Approximately 4% of (A)FAP patients have a somatic mosaic APC mutation, which increases to ~20% when only de novo cases are considered. More information on APC-associated polyposis is available at http://www.ncbi.nlm.nih.gov/books/NBK1345/.
Among the various defects in the APC gene that have been found in patients, are deletions and duplications of complete exons, which are usually missed by standard sequence analysis. The MLPA technique can detect most of these deletions and duplications and therefore complements sequence analysis of the APC gene. It is expected that 8-12% of all APC mutations in most populations are large rearrangements that can be detected with this MLPA probemix (Jarry et al. 2011; Kerr et al. 2013). Of note, several clinically relevant rearrangements of only the APC promoter region are reported and have been associated with FAP (Snow et al. 2014; Kadiyska et al. 2014; Kalbfleisch et al. 2015; Marabelli et al. 2017), all of which can be detected with this probemix.
Mutations in the MUTYH gene also result in a hereditary predisposition to colon and gastric cancer, which is referred to as MUTYH-associated polyposis (MAP). In contrast to the APC-associated disease FAP, MAP is an autosomal recessive disorder and is considered less severe: polyps do not appear until adulthood and are less numerous than those found in patients with APC gene mutations. Nevertheless, phenotypes of APC- and MUTYH-related CRC partly overlap. Therefore, six probes for the MUTYH gene are included in this P043-E1 APC probemix, two of which will only generate a signal when the common c.536A>G (p.Tyr179Cys) or c.1187G>A (p.Gly396Asp) mutations are present. The c.536A>G (p.Tyr179Cys) and c.1187G>A (p.Gly396Asp) variants are carried by ~1%-2% of the general population and account for ≥90% of all MUTYH pathogenic variants in northern European populations. Up to 70% of MAP patients harbours at least one of these variants (Aretz et al. 2013). Since the MUTYH gene is small (11 kilobases (kb)), the four copy number detection MLPA probes are expected to detect a substantial part of MUTYH copy number changes. For instance, the most frequent CNV in MUTYH – a deletion of exon 4-16 that is reported in multiple patients (Castillejo et al. 2014) – can be detected with two probes in this probemix. More information on MAP is available at GeneReviews: MUTYH Polyposis. For complete exon coverage of MUTYH the SALSA MLPA Probemix P378 MUTYH is available.
A recurrent duplication of ~40 kb directly upstream of the GREM1 gene is known to lead to HMPS1. Patients with HMPS1 have a predisposition for developing CRC (Jaeger et al. 2012). Presence of this duplication is predicted to cause reduced bone morphogenetic protein (BMP) pathway activity, a mechanism that underlies tumorigenesis in juvenile polyposis of the large bowel. Several additional duplications in the GREM1 upstream region have been found: e.g. a duplication of the upstream region and the whole GREM1 gene of ~57 kb has been described in one patient with sigmoid colon carcinoma (Venkatachalam et al. 2011); a duplication of ~16 kb has been described in members of a family presenting with atypical FAP (Rohlin et al. 2016); and a duplication of ~24 kb in a patient with multiple colon polyps has been reported (McKenna et al. 2019). Two probes for the relevant region directly upstream of GREM1 are included in this probemix; both probes detect the 40 kb, 57 kb and 24 kb duplications and the 16 kb duplication can be detected by one of these probes (probe number 21272-L23310 at 217 nucleotides (nt)). For extended coverage of the GREM1 region the SALSA MLPA Probemix P378 MUTYH is available. More information on HMPS1 is available at OMIM.
SALSA MLPA Probemix P043 APC is CE-marked under the IVDR for in vitro diagnostic (IVD) use in Europe. This assay has also been registered for IVD use in Costa Rica and Israel.
This assay is for research use only (RUO) in all other territories.
SALSA Binning DNA SD022 is an artificial DNA sample with a signal for all probes in the P043 APC probemix. Inclusion of a reaction with SD022 in initial experiments and in experiments following a change in electrophoresis conditions is recommended to aid in the creation of a bin set that links peaks to the probes that produce them. Binning DNA cannot be used as a reference sample in the MLPA data analysis, and cannot be used to quantify the signals of mutation-specific probes.
A vial of SALSA Binning DNA SD022 is included with every order of the P043 APC probemix, but it is possible to order additional vials separately.
For more information, see the product description.
Translations of the product description in selected European languages are available upon request. Please contact us or one of our local sales partners. Translations of the MLPA General Protocol in selected languages are available here.
The Summary of Safety and Performance (SSP) is also available upon request.
A general SALSA MLPA Reagent Kit is required for MLPA experiments (to be ordered separately).
A vial is included with every order of this probemix, but additional vials can also be purchased separately.
The prices above are list prices for direct orders from MRC Holland. Contact us for a quote that takes discounts and additional costs (such as shipping costs) into account. Different prices apply for orders through one of our sales partners; contact your local supplier for a quote.
Inclusion of a positive sample is usually not required, but can be useful for the analysis of your experiments. MRC Holland has very limited access to positive samples and cannot supply such samples. We recommend using positive samples from your own collection. Alternatively, you can use positive samples from an online biorepository, such as the Coriell Institute.
The commercially available positive samples below can be used with the current (E1) version of this product.
MRC Holland offers various different assays for Lynch syndrome and polyposis syndrome. The table below indicates which product can be used for which target gene(s).
| Currently Viewing | Currently Viewing | Currently Viewing | Currently Viewing | Currently Viewing | Currently Viewing | Currently Viewing | Currently Viewing | ||
|---|---|---|---|---|---|---|---|---|---|
| D001/D002 | P003 | P248 | P008 | P072 | ME011 | P043 | P378 | ||
| Properties | CE-marked | no | yes | yes | yes | yes | yes | yes | yes |
| Technique | digitalMLPA | MLPA | MLPA | MLPA | MLPA | MS-MLPA | MLPA | MLPA | |
| Lynch syndrome (HNPCC) | MLH1 | ✓ | ✓ | ✓ | ✓ | ||||
| MSH2 | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| MSH6 | ✓ | ✓ | ✓ | ||||||
| PMS2 | ✓ | ✓ | ✓ | ||||||
| EPCAM | ✓ | ✓ | ✓ | ✓ | |||||
| Polyposis syndrome | FAP/AFAP: APC | ✓ | ✓ | ||||||
| MAP: MUTYH | ✓ | ✓ | ✓ | ✓ | |||||
| Product page | D001/D002 | P003 | P248 | P008 | P072 | ME011 | P043 | P378 | |